Cetirizine hydrochloride is a Small Molecule owned by NicOx, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.
Cetirizine hydrochloride competes with histamine for binding at H1-receptor sites on the effector cell surface, which blocks the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. By blocking H1-receptor, the drug candidate significantly reduces the effects of allergens.
The revenue for Cetirizine hydrochloride is expected to reach a total of $199m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cetirizine hydrochloride NPV Report.
Cetirizine hydrochloride Overview
Cetirizine hydrochloride (AC-170, Zerviate) is a diphenylmethane derivative, acts as an antihistamine agent. It is formulated as solution for ophthalmic route of administration. Zerviate is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Cetirizine hydrochloride (OT-1001) is under development for the treatment of allergic conjunctivitis in China.
Ocumension Therapeutics Overview
Ocumension Therapeutics (Ocumension) develops and provides prescription medicines that meet the evolving needs of patients, healthcare professionals, and caregivers. Ocumension is headquartered in Suzhou, Suzhou, China.
The company reported revenues of (Renminbi) CNY56.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY13.1 million in FY2020. The operating loss of the company was CNY246.1 million in FY2021, compared to an operating loss of CNY2,264.8 million in FY2020. The net loss of the company was CNY260 million in FY2021, compared to a net loss of CNY2,264.9 million in FY2020.
Quick View – Cetirizine hydrochloride
|Highest Development Stage|